SlideShare a Scribd company logo
1 of 11
Download to read offline
Moving from product supplies
to a global solution for your processes
Christophe Grimm| Hélène Panier
June 2016
Agenda
• Antibody processes trends
• Suppliers implication
• A platform approach for your product life-cycle
• The Platform is greater then the sum of its parts
Molecules in Development
Questions:
⇒ Why re-invent the wheel for
each candidate? “Platform”
approach
⇒ Impact on processes
technologies and challenges?
⇒ Can suppliers adapt better to
support those trends?
Source: Analysis from Global Data extract August 2015
 Amongs large molecules, 75% of
pipelines in early stage:
information about trends
 Antibodies, Proteins and Vaccines
remain the largest segments
Discovery
Pre-Clinical
Phase 1
Phase 2
Phase 3
75%
Discovery & pre-clinical phase; segmentation by molecule type
Molecules in Development
« Antibody » segment => Diversification
Mabs remain dominant segment but other sub-categories
are emerging:
 Mabs Biosimilars is a growing segment (89% of them are
in pre-clinical/discovery)
 ADCs is a growing trend, a 11B$ market is estimated by
2025
 New Antibodies formats are emerging: bi/tri-specifics
antibodies, fragments, fusion-proteins...which could
represent up to 10% of the antibodies market in the next
10 years
Mab: discovery & preclinical candidates
Σ=2000
Source: Analysis from Global Data extract August 2015
 Does the classical Mab process apply to those new trends?
 Which innovations are required to enable those changes?
 Cost impacts and timelines to market?
Trends within the “Antibody” segment
Impact on Processes & Technologies
How suppliers can better support?
Source: Analysis from Global Data extract August 2015
 Flexibility
 Standardization
 “Platform/ Tool Box”
approach
to better support
 Multi-products facilities
 Tech-transfers
 Outsourcing strategies
 COGs optimization
 ...
“We want to eliminate the view of upstream and downstream.
We want ONESTREAM”
“We are looking to create a fully integrated continuous manufacturing
platform for biosimilar mAb production based in single use technologies
Re-defining process standards
• Specific validation
• Custom design
• Complex operations
• Automated operations
• Re-usable
Stainless Steel
• Pre-qualified components
by supplier
• Manual operations
• Supply chain management
• Consumables
Single-Use
• QbD implementation
• Pre-qualified process
steps
• Standard consumables
• Scalable (up & down)
Flexible
manufacturing
Equipment features approach
• Does the equipment features fit my process needs?
• How to qualify my scale down model?
• How to validate all equipment interactions?
MediaPrep Bioreaction Harvest Capture Polishing 1 Polishing 2
Virus
removal
Diafiltration
X X X X X X X
Equipment
F1
F2
F3
F5
F7
F6
F8
F4
Process Platform Trend
Media | Buffer Preparation
StorageMixing
Upstream Process
Seed
Bioreactor
Production
Bioreactor
FlexActFlexAct
Depth
Filtration
Micro
Filtration
Storage
Protein A
Chromatography
Post-Viral Downstream Process
Virus
Filtration
Sterile
Filtration
Filling Freezing
Sterile
Filtration
CEX
Chromatography
Low-pH
Virus
Inactivation
Storage Storage
Polishing
Membrane
Adsorption
FlexAct Storage
UF|DF
Recirculation
MixingFlexAct
Pre-Viral Downstream Process
Product Life-Cycle Platform approach
• How to do my process efficiently?
• How to better integrate suppliers?
PLATFORM
CLD
Media Optimization
ProcessOptimization
Scalability
Process caracterisation
Standardization
Flexibilitybydesign
Analytics
Quality by Design
Multiproduct manufacturing
PAT
ManufacturingExcellence
 Consistant approach for all
products/processes
 Full support & guidance through
the life cycle of your products
 Holistic view of the needs
 Standardization
 Facilitating tech transfers
 Facilitating operators trainings
 Enhance flexibility
 Better predictability
A platform is greater than the sum of its parts!
How many projects have been delayed or even stopped because the
process could not be adapted to industrial tool? Impact on cost?
1 + 1 = 3
11
Distance between perception and reality is the innovator’s playground
Travis Kalanick

More Related Content

What's hot

General presentation XB
General presentation XBGeneral presentation XB
General presentation XBAmlieJanssen
 
Integrated utilization of high-throughput bioreactors & high-throughput analy...
Integrated utilization of high-throughput bioreactors & high-throughput analy...Integrated utilization of high-throughput bioreactors & high-throughput analy...
Integrated utilization of high-throughput bioreactors & high-throughput analy...KBI Biopharma
 
Boedeker Bayer BILS 2016
Boedeker Bayer BILS 2016Boedeker Bayer BILS 2016
Boedeker Bayer BILS 2016GBX Events
 
Managing Raw Material Variability Over the Life-cycle of a Molecule
Managing Raw Material Variability Over the Life-cycle of a MoleculeManaging Raw Material Variability Over the Life-cycle of a Molecule
Managing Raw Material Variability Over the Life-cycle of a MoleculeKBI Biopharma
 
Strategic Considerations for Implementing Single-Use Technologies in Vaccine ...
Strategic Considerations for Implementing Single-Use Technologies in Vaccine ...Strategic Considerations for Implementing Single-Use Technologies in Vaccine ...
Strategic Considerations for Implementing Single-Use Technologies in Vaccine ...Dr. Priyabrata Pattnaik
 
From preclinical to commercial: The evolution of ADC manufacturing expertise ...
From preclinical to commercial: The evolution of ADC manufacturing expertise ...From preclinical to commercial: The evolution of ADC manufacturing expertise ...
From preclinical to commercial: The evolution of ADC manufacturing expertise ...MilliporeSigma
 
The Future of Bioprocessing – What you need to know.
The Future of Bioprocessing – What you need to know.The Future of Bioprocessing – What you need to know.
The Future of Bioprocessing – What you need to know.MilliporeSigma
 
Complete single-use ADC technology from development through scale-up
Complete single-use ADC technology from development through scale-up	Complete single-use ADC technology from development through scale-up
Complete single-use ADC technology from development through scale-up MilliporeSigma
 
Newcastle BILS 2016
Newcastle BILS 2016Newcastle BILS 2016
Newcastle BILS 2016GBX Events
 
Webinar: Post Approval Changes in Biologics Manufacturing - A Practical Asses...
Webinar: Post Approval Changes in Biologics Manufacturing - A Practical Asses...Webinar: Post Approval Changes in Biologics Manufacturing - A Practical Asses...
Webinar: Post Approval Changes in Biologics Manufacturing - A Practical Asses...MilliporeSigma
 
HPLC Purification - main considerations
HPLC Purification - main considerationsHPLC Purification - main considerations
HPLC Purification - main considerationsNovasep
 
Successful Drug Development with Synthetic Lipids: Critical Aspects and Strat...
Successful Drug Development with Synthetic Lipids: Critical Aspects and Strat...Successful Drug Development with Synthetic Lipids: Critical Aspects and Strat...
Successful Drug Development with Synthetic Lipids: Critical Aspects and Strat...MilliporeSigma
 
Kemwell biologics presentation bp April 2018
Kemwell biologics presentation bp April 2018Kemwell biologics presentation bp April 2018
Kemwell biologics presentation bp April 2018MithaliRosario
 
Employing Innovative Platform Manufacturing and Biosafety Testing for your Ge...
Employing Innovative Platform Manufacturing and Biosafety Testing for your Ge...Employing Innovative Platform Manufacturing and Biosafety Testing for your Ge...
Employing Innovative Platform Manufacturing and Biosafety Testing for your Ge...MilliporeSigma
 
HJB CDMO Introduction (2019)
HJB CDMO Introduction (2019)HJB CDMO Introduction (2019)
HJB CDMO Introduction (2019)XiaomingJerryYang
 
USP <665> draft standard : A rational risk-based approach to characterization...
USP <665> draft standard : A rational risk-based approach to characterization...USP <665> draft standard : A rational risk-based approach to characterization...
USP <665> draft standard : A rational risk-based approach to characterization...MilliporeSigma
 
The Emprove® Program: Introduction of New Portfolio Additions
The Emprove® Program: Introduction of New Portfolio AdditionsThe Emprove® Program: Introduction of New Portfolio Additions
The Emprove® Program: Introduction of New Portfolio AdditionsMerck Life Sciences
 
Reducing time to clinic with CHOvolution™ cell line
Reducing time to clinic with CHOvolution™ cell line Reducing time to clinic with CHOvolution™ cell line
Reducing time to clinic with CHOvolution™ cell line Stavros Theocharidis
 
Latest Updates in Biosafety Testing for Gene Therapy
Latest Updates in Biosafety Testing for Gene TherapyLatest Updates in Biosafety Testing for Gene Therapy
Latest Updates in Biosafety Testing for Gene TherapyMilliporeSigma
 

What's hot (20)

General presentation XB
General presentation XBGeneral presentation XB
General presentation XB
 
Integrated utilization of high-throughput bioreactors & high-throughput analy...
Integrated utilization of high-throughput bioreactors & high-throughput analy...Integrated utilization of high-throughput bioreactors & high-throughput analy...
Integrated utilization of high-throughput bioreactors & high-throughput analy...
 
Boedeker Bayer BILS 2016
Boedeker Bayer BILS 2016Boedeker Bayer BILS 2016
Boedeker Bayer BILS 2016
 
Managing Raw Material Variability Over the Life-cycle of a Molecule
Managing Raw Material Variability Over the Life-cycle of a MoleculeManaging Raw Material Variability Over the Life-cycle of a Molecule
Managing Raw Material Variability Over the Life-cycle of a Molecule
 
Mycenax Introduction_
Mycenax Introduction_Mycenax Introduction_
Mycenax Introduction_
 
Strategic Considerations for Implementing Single-Use Technologies in Vaccine ...
Strategic Considerations for Implementing Single-Use Technologies in Vaccine ...Strategic Considerations for Implementing Single-Use Technologies in Vaccine ...
Strategic Considerations for Implementing Single-Use Technologies in Vaccine ...
 
From preclinical to commercial: The evolution of ADC manufacturing expertise ...
From preclinical to commercial: The evolution of ADC manufacturing expertise ...From preclinical to commercial: The evolution of ADC manufacturing expertise ...
From preclinical to commercial: The evolution of ADC manufacturing expertise ...
 
The Future of Bioprocessing – What you need to know.
The Future of Bioprocessing – What you need to know.The Future of Bioprocessing – What you need to know.
The Future of Bioprocessing – What you need to know.
 
Complete single-use ADC technology from development through scale-up
Complete single-use ADC technology from development through scale-up	Complete single-use ADC technology from development through scale-up
Complete single-use ADC technology from development through scale-up
 
Newcastle BILS 2016
Newcastle BILS 2016Newcastle BILS 2016
Newcastle BILS 2016
 
Webinar: Post Approval Changes in Biologics Manufacturing - A Practical Asses...
Webinar: Post Approval Changes in Biologics Manufacturing - A Practical Asses...Webinar: Post Approval Changes in Biologics Manufacturing - A Practical Asses...
Webinar: Post Approval Changes in Biologics Manufacturing - A Practical Asses...
 
HPLC Purification - main considerations
HPLC Purification - main considerationsHPLC Purification - main considerations
HPLC Purification - main considerations
 
Successful Drug Development with Synthetic Lipids: Critical Aspects and Strat...
Successful Drug Development with Synthetic Lipids: Critical Aspects and Strat...Successful Drug Development with Synthetic Lipids: Critical Aspects and Strat...
Successful Drug Development with Synthetic Lipids: Critical Aspects and Strat...
 
Kemwell biologics presentation bp April 2018
Kemwell biologics presentation bp April 2018Kemwell biologics presentation bp April 2018
Kemwell biologics presentation bp April 2018
 
Employing Innovative Platform Manufacturing and Biosafety Testing for your Ge...
Employing Innovative Platform Manufacturing and Biosafety Testing for your Ge...Employing Innovative Platform Manufacturing and Biosafety Testing for your Ge...
Employing Innovative Platform Manufacturing and Biosafety Testing for your Ge...
 
HJB CDMO Introduction (2019)
HJB CDMO Introduction (2019)HJB CDMO Introduction (2019)
HJB CDMO Introduction (2019)
 
USP <665> draft standard : A rational risk-based approach to characterization...
USP <665> draft standard : A rational risk-based approach to characterization...USP <665> draft standard : A rational risk-based approach to characterization...
USP <665> draft standard : A rational risk-based approach to characterization...
 
The Emprove® Program: Introduction of New Portfolio Additions
The Emprove® Program: Introduction of New Portfolio AdditionsThe Emprove® Program: Introduction of New Portfolio Additions
The Emprove® Program: Introduction of New Portfolio Additions
 
Reducing time to clinic with CHOvolution™ cell line
Reducing time to clinic with CHOvolution™ cell line Reducing time to clinic with CHOvolution™ cell line
Reducing time to clinic with CHOvolution™ cell line
 
Latest Updates in Biosafety Testing for Gene Therapy
Latest Updates in Biosafety Testing for Gene TherapyLatest Updates in Biosafety Testing for Gene Therapy
Latest Updates in Biosafety Testing for Gene Therapy
 

Similar to Antibody congress Montpellier_June 2016_rev1

Highly accelerated platforms for mAb and next generation mAb manufacturing
Highly accelerated platforms for mAb and next generation mAb manufacturingHighly accelerated platforms for mAb and next generation mAb manufacturing
Highly accelerated platforms for mAb and next generation mAb manufacturingKBI Biopharma
 
Covering a Spectrum of New Product Development Technologies - From Cells to C...
Covering a Spectrum of New Product Development Technologies - From Cells to C...Covering a Spectrum of New Product Development Technologies - From Cells to C...
Covering a Spectrum of New Product Development Technologies - From Cells to C...KBI Biopharma
 
Orphan Biopharmaceuticals & the CDMO
Orphan Biopharmaceuticals & the CDMOOrphan Biopharmaceuticals & the CDMO
Orphan Biopharmaceuticals & the CDMOKBI Biopharma
 
Process Development for Cell Therapy and Viral Gene Therapy
Process Development for Cell Therapy and Viral Gene TherapyProcess Development for Cell Therapy and Viral Gene Therapy
Process Development for Cell Therapy and Viral Gene TherapyMilliporeSigma
 
Process Development for Cell Therapy and Viral Gene Therapy
Process Development for Cell Therapy and Viral Gene TherapyProcess Development for Cell Therapy and Viral Gene Therapy
Process Development for Cell Therapy and Viral Gene TherapyMerck Life Sciences
 
Next-Generation Bioprocessing Monitoring to Enable Smart Data Management and ...
Next-Generation Bioprocessing Monitoring to Enable Smart Data Management and ...Next-Generation Bioprocessing Monitoring to Enable Smart Data Management and ...
Next-Generation Bioprocessing Monitoring to Enable Smart Data Management and ...Merck Life Sciences
 
Next-Generation Bioprocessing Monitoring to Enable Smart Data Management and ...
Next-Generation Bioprocessing Monitoring to Enable Smart Data Management and ...Next-Generation Bioprocessing Monitoring to Enable Smart Data Management and ...
Next-Generation Bioprocessing Monitoring to Enable Smart Data Management and ...MilliporeSigma
 
The Biocontinuum™ Seed Train Platform
The Biocontinuum™ Seed Train PlatformThe Biocontinuum™ Seed Train Platform
The Biocontinuum™ Seed Train PlatformMilliporeSigma
 
The Biocontinuum™ Seed Train Platform
The Biocontinuum™ Seed Train PlatformThe Biocontinuum™ Seed Train Platform
The Biocontinuum™ Seed Train PlatformMerck Life Sciences
 
Streamlining Biopharmaceutical Cell Line Development - Reducing risk and decr...
Streamlining Biopharmaceutical Cell Line Development - Reducing risk and decr...Streamlining Biopharmaceutical Cell Line Development - Reducing risk and decr...
Streamlining Biopharmaceutical Cell Line Development - Reducing risk and decr...MilliporeSigma
 
Dcn inovatec presentation final
Dcn inovatec presentation finalDcn inovatec presentation final
Dcn inovatec presentation finalFabiana Tarabal
 
Industrial Bioprocessing webinar.pptx
Industrial Bioprocessing webinar.pptxIndustrial Bioprocessing webinar.pptx
Industrial Bioprocessing webinar.pptxShubham Chinchulkar
 
Accelerating vaccine development and manufacturing
Accelerating vaccine development and manufacturingAccelerating vaccine development and manufacturing
Accelerating vaccine development and manufacturingDr. Priyabrata Pattnaik
 
Platforms for mAb Commercialization
Platforms for mAb Commercialization Platforms for mAb Commercialization
Platforms for mAb Commercialization KBI Biopharma
 
Smart Data Management and Advanced Analytics with Bio4C™ ProcessPad
Smart Data Management and Advanced Analytics with Bio4C™ ProcessPadSmart Data Management and Advanced Analytics with Bio4C™ ProcessPad
Smart Data Management and Advanced Analytics with Bio4C™ ProcessPadMilliporeSigma
 
Smart Data Management and Advanced Analytics with Bio4C™ ProcessPad
Smart Data Management and Advanced Analytics with Bio4C™ ProcessPadSmart Data Management and Advanced Analytics with Bio4C™ ProcessPad
Smart Data Management and Advanced Analytics with Bio4C™ ProcessPadMerck Life Sciences
 
Chinese Microfluidics Industry 2018 Report by Yole Developpement
Chinese Microfluidics Industry 2018 Report by Yole DeveloppementChinese Microfluidics Industry 2018 Report by Yole Developpement
Chinese Microfluidics Industry 2018 Report by Yole DeveloppementYole Developpement
 
From preclinical to commercial: The evolution of ADC manufacturing expertise ...
From preclinical to commercial: The evolution of ADC manufacturing expertise ...From preclinical to commercial: The evolution of ADC manufacturing expertise ...
From preclinical to commercial: The evolution of ADC manufacturing expertise ...Merck Life Sciences
 

Similar to Antibody congress Montpellier_June 2016_rev1 (20)

Highly accelerated platforms for mAb and next generation mAb manufacturing
Highly accelerated platforms for mAb and next generation mAb manufacturingHighly accelerated platforms for mAb and next generation mAb manufacturing
Highly accelerated platforms for mAb and next generation mAb manufacturing
 
Covering a Spectrum of New Product Development Technologies - From Cells to C...
Covering a Spectrum of New Product Development Technologies - From Cells to C...Covering a Spectrum of New Product Development Technologies - From Cells to C...
Covering a Spectrum of New Product Development Technologies - From Cells to C...
 
Orphan Biopharmaceuticals & the CDMO
Orphan Biopharmaceuticals & the CDMOOrphan Biopharmaceuticals & the CDMO
Orphan Biopharmaceuticals & the CDMO
 
Process Development for Cell Therapy and Viral Gene Therapy
Process Development for Cell Therapy and Viral Gene TherapyProcess Development for Cell Therapy and Viral Gene Therapy
Process Development for Cell Therapy and Viral Gene Therapy
 
Process Development for Cell Therapy and Viral Gene Therapy
Process Development for Cell Therapy and Viral Gene TherapyProcess Development for Cell Therapy and Viral Gene Therapy
Process Development for Cell Therapy and Viral Gene Therapy
 
Next-Generation Bioprocessing Monitoring to Enable Smart Data Management and ...
Next-Generation Bioprocessing Monitoring to Enable Smart Data Management and ...Next-Generation Bioprocessing Monitoring to Enable Smart Data Management and ...
Next-Generation Bioprocessing Monitoring to Enable Smart Data Management and ...
 
Next-Generation Bioprocessing Monitoring to Enable Smart Data Management and ...
Next-Generation Bioprocessing Monitoring to Enable Smart Data Management and ...Next-Generation Bioprocessing Monitoring to Enable Smart Data Management and ...
Next-Generation Bioprocessing Monitoring to Enable Smart Data Management and ...
 
The Biocontinuum™ Seed Train Platform
The Biocontinuum™ Seed Train PlatformThe Biocontinuum™ Seed Train Platform
The Biocontinuum™ Seed Train Platform
 
The Biocontinuum™ Seed Train Platform
The Biocontinuum™ Seed Train PlatformThe Biocontinuum™ Seed Train Platform
The Biocontinuum™ Seed Train Platform
 
Streamlining Biopharmaceutical Cell Line Development - Reducing risk and decr...
Streamlining Biopharmaceutical Cell Line Development - Reducing risk and decr...Streamlining Biopharmaceutical Cell Line Development - Reducing risk and decr...
Streamlining Biopharmaceutical Cell Line Development - Reducing risk and decr...
 
Dcn inovatec presentation final
Dcn inovatec presentation finalDcn inovatec presentation final
Dcn inovatec presentation final
 
Industrial Bioprocessing webinar.pptx
Industrial Bioprocessing webinar.pptxIndustrial Bioprocessing webinar.pptx
Industrial Bioprocessing webinar.pptx
 
DCN Company Profile 2015
DCN Company Profile 2015DCN Company Profile 2015
DCN Company Profile 2015
 
Accelerating vaccine development and manufacturing
Accelerating vaccine development and manufacturingAccelerating vaccine development and manufacturing
Accelerating vaccine development and manufacturing
 
Platforms for mAb Commercialization
Platforms for mAb Commercialization Platforms for mAb Commercialization
Platforms for mAb Commercialization
 
Cell line development services
Cell line development servicesCell line development services
Cell line development services
 
Smart Data Management and Advanced Analytics with Bio4C™ ProcessPad
Smart Data Management and Advanced Analytics with Bio4C™ ProcessPadSmart Data Management and Advanced Analytics with Bio4C™ ProcessPad
Smart Data Management and Advanced Analytics with Bio4C™ ProcessPad
 
Smart Data Management and Advanced Analytics with Bio4C™ ProcessPad
Smart Data Management and Advanced Analytics with Bio4C™ ProcessPadSmart Data Management and Advanced Analytics with Bio4C™ ProcessPad
Smart Data Management and Advanced Analytics with Bio4C™ ProcessPad
 
Chinese Microfluidics Industry 2018 Report by Yole Developpement
Chinese Microfluidics Industry 2018 Report by Yole DeveloppementChinese Microfluidics Industry 2018 Report by Yole Developpement
Chinese Microfluidics Industry 2018 Report by Yole Developpement
 
From preclinical to commercial: The evolution of ADC manufacturing expertise ...
From preclinical to commercial: The evolution of ADC manufacturing expertise ...From preclinical to commercial: The evolution of ADC manufacturing expertise ...
From preclinical to commercial: The evolution of ADC manufacturing expertise ...
 

Antibody congress Montpellier_June 2016_rev1

  • 1. Moving from product supplies to a global solution for your processes Christophe Grimm| Hélène Panier June 2016
  • 2. Agenda • Antibody processes trends • Suppliers implication • A platform approach for your product life-cycle • The Platform is greater then the sum of its parts
  • 3. Molecules in Development Questions: ⇒ Why re-invent the wheel for each candidate? “Platform” approach ⇒ Impact on processes technologies and challenges? ⇒ Can suppliers adapt better to support those trends? Source: Analysis from Global Data extract August 2015  Amongs large molecules, 75% of pipelines in early stage: information about trends  Antibodies, Proteins and Vaccines remain the largest segments Discovery Pre-Clinical Phase 1 Phase 2 Phase 3 75% Discovery & pre-clinical phase; segmentation by molecule type
  • 4. Molecules in Development « Antibody » segment => Diversification Mabs remain dominant segment but other sub-categories are emerging:  Mabs Biosimilars is a growing segment (89% of them are in pre-clinical/discovery)  ADCs is a growing trend, a 11B$ market is estimated by 2025  New Antibodies formats are emerging: bi/tri-specifics antibodies, fragments, fusion-proteins...which could represent up to 10% of the antibodies market in the next 10 years Mab: discovery & preclinical candidates Σ=2000 Source: Analysis from Global Data extract August 2015  Does the classical Mab process apply to those new trends?  Which innovations are required to enable those changes?  Cost impacts and timelines to market? Trends within the “Antibody” segment
  • 5. Impact on Processes & Technologies How suppliers can better support? Source: Analysis from Global Data extract August 2015  Flexibility  Standardization  “Platform/ Tool Box” approach to better support  Multi-products facilities  Tech-transfers  Outsourcing strategies  COGs optimization  ... “We want to eliminate the view of upstream and downstream. We want ONESTREAM” “We are looking to create a fully integrated continuous manufacturing platform for biosimilar mAb production based in single use technologies
  • 6. Re-defining process standards • Specific validation • Custom design • Complex operations • Automated operations • Re-usable Stainless Steel • Pre-qualified components by supplier • Manual operations • Supply chain management • Consumables Single-Use • QbD implementation • Pre-qualified process steps • Standard consumables • Scalable (up & down) Flexible manufacturing
  • 7. Equipment features approach • Does the equipment features fit my process needs? • How to qualify my scale down model? • How to validate all equipment interactions? MediaPrep Bioreaction Harvest Capture Polishing 1 Polishing 2 Virus removal Diafiltration X X X X X X X Equipment F1 F2 F3 F5 F7 F6 F8 F4
  • 8. Process Platform Trend Media | Buffer Preparation StorageMixing Upstream Process Seed Bioreactor Production Bioreactor FlexActFlexAct Depth Filtration Micro Filtration Storage Protein A Chromatography Post-Viral Downstream Process Virus Filtration Sterile Filtration Filling Freezing Sterile Filtration CEX Chromatography Low-pH Virus Inactivation Storage Storage Polishing Membrane Adsorption FlexAct Storage UF|DF Recirculation MixingFlexAct Pre-Viral Downstream Process
  • 9. Product Life-Cycle Platform approach • How to do my process efficiently? • How to better integrate suppliers? PLATFORM CLD Media Optimization ProcessOptimization Scalability Process caracterisation Standardization Flexibilitybydesign Analytics Quality by Design Multiproduct manufacturing PAT ManufacturingExcellence
  • 10.  Consistant approach for all products/processes  Full support & guidance through the life cycle of your products  Holistic view of the needs  Standardization  Facilitating tech transfers  Facilitating operators trainings  Enhance flexibility  Better predictability A platform is greater than the sum of its parts! How many projects have been delayed or even stopped because the process could not be adapted to industrial tool? Impact on cost? 1 + 1 = 3
  • 11. 11 Distance between perception and reality is the innovator’s playground Travis Kalanick